2016
Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community
Protásio B, Matutino A, Lage L, Santana I, Ramos R, Sabbaga J, Capareli F, Saragiotto D, Riechelmann R, Hoff P. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community. Clinical Colorectal Cancer 2016, 16: 65-72. PMID: 27515842, DOI: 10.1016/j.clcc.2016.07.001.Peer-Reviewed Original ResearchConceptsStage III colorectal cancerColorectal cancerClinical trialsHigh riskResected stage III colorectal cancerLogistic regression multivariate analysisStage III CRC patientsDisease-free survivalPredictors of recurrenceRegression multivariate analysisAge 70 yearsLarge cancer centerAdjuvant chemotherapyAdjuvant oxaliplatinFit patientsNeurotoxicity gradeUrgent surgeryAdjuvant regimenAdverse eventsCohort studyCommunity patientsConsecutive patientsCRC patientsMedian agePrognostic factors
2014
1391P Acute Infusional Reactions to Chemotherapy in an Outpatient Unit: Experience from 21,394 Treatment Cycles in Brazil
Isaacsson P, Teixeira M, Scaranti M, Matutino A, Negrao M, Fraile N, Souza K, Yen C, Pinheiro G, Hoff P, G.C.. 1391P Acute Infusional Reactions to Chemotherapy in an Outpatient Unit: Experience from 21,394 Treatment Cycles in Brazil. Annals Of Oncology 2014, 25: iv487. DOI: 10.1093/annonc/mdu353.5.Peer-Reviewed Original ResearchInfusional reactionsMedian body mass indexDefinitive treatment interruptionECOG PS 0Frequent primary siteIntravenous cytotoxic chemotherapyMedian lymphocyte countCells/mm3Body mass indexTreatment interruptionAdequate prophylaxisCytotoxic chemotherapyLymphocyte countMedian hemoglobinMetastatic diseaseSystemic treatmentMedian ageBack painMass indexChemotherapy infusionCancer CenterChemotherapy unitCommon signsOutpatient unitSevere reactions